Clinical Validation of ADAM9 as a Prognostic Biomarker in Oral Cancer
Oral Diseases · 2025
DOI: 10.1111/odi.15383 ↗Kurz gefasst
Fachartikel in der Zeitschrift Oral Diseases, 2025. Verfasst von Jeng-Wei Lu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Bioscience and Biotechnology, National Taiwan Ocean University, Keelung, Taiwan. Hauptthemen laut MEDLINE: Mouth Neoplasms, ADAM Proteins, Membrane Proteins, Biomarkers, Tumor. Die Arbeit nennt 62 Literaturangaben. Gefördert von: National Chung-Hsing University, Changhua Christian Hospital.
Abstract (Originalsprache)
Background
Oral cancer has a high incidence in Taiwan, and identifying prognostic biomarkers is crucial. This study investigated the role of a disintegrin and metalloprotease 9 (ADAM9) in oral cancer progression and outcomes.
Methods
This study investigated ADAM9 protein expression in 353 oral cancer tissue specimens through immunohistochemical (IHC) analysis.
Results
The analysis revealed that, among the 353 patients, 21 (6%) exhibited low ADAM9 expression, while the remaining 332 patients (94%) showed high ADAM9 expression, which correlated with advanced T status, poor overall survival, and unfavorable prognosis. Kaplan–Meier analysis confirmed that higher ADAM9 expression predicted significantly worse survival. Univariate and multivariate analyses identified ADAM9, histological grade, and AJCC stage as independent prognostic factors. Functionally, ADAM9 silencing in SAS and OC2 cells inhibited invasion and migration, downregulating matrix metalloproteinase 9 (MMP9) and matrix metalloproteinase 14 (MMP14). siRNA‐mediated ADAM9 knockdown also reduced cell viability and migration, as confirmed by cell counting kit‐8 and transwell assays. The Cancer Genome Atlas (TCGA) analysis further revealed a positive correlation between ADAM9 mRNA levels and matrix metalloproteinase 2 (MMP2) or MMP14 expression in oral cancer patients.
Conclusions
This study identifies ADAM9 as a key driver of oral cancer in a Taiwanese cohort and highlights its diagnostic and therapeutic potential.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Bioscience and Biotechnology, National Taiwan Ocean University, Keelung, Taiwan.
- Biotech Research and Innovation Centre, University of Copenhagen, Copenhagen, Denmark.
- The Finsen Laboratory, Rigshospitalet/National University Hospital, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
- Institute of Biomedical Sciences, National Chung Hsing University, Taichung, Taiwan.
- Department of Post-Baccalaureate Medicine, College of Medicine, National Chung Hsing University, Taichung, Taiwan.
- Graduate Institute of Clinical Nursing, National Chung Hsing University, Taichung, Taiwan.
ORCID-Profile: Jeng-Wei Lu
Förderung
- National Chung-Hsing University
- Changhua Christian Hospital
Zitieren
APA
Lu, J. W., Shih, P. C., Chuang, S. M., Tu, W. J., Tsai, M. H., Tsai, Y. J., & Lin, S. H. (2025). Clinical Validation of ADAM9 as a Prognostic Biomarker in Oral Cancer. Oral Diseases. https://doi.org/10.1111/odi.15383
Vancouver
Lu JW, Shih PC, Chuang SM, Tu WJ, Tsai MH, Tsai YJ, et al. Clinical Validation of ADAM9 as a Prognostic Biomarker in Oral Cancer. Oral Diseases. 2025. doi:10.1111/odi.15383
BibTeX
@article{Lu2025,
author = {Lu, Jeng-Wei and Shih, Pei-Chen and Chuang, Show-Mei and Tu, Wan-Jung and Tsai, Ming-Heng and Tsai, Yun-Jung and Lin, Shu-Hui},
title = {Clinical Validation of ADAM9 as a Prognostic Biomarker in Oral Cancer},
journal = {Oral Diseases},
year = {2025},
doi = {10.1111/odi.15383}
}
EUVIMED